GRINCH: Glycemic Response to an Innovative Cookie to Promote Human Health

Sponsor
KU Leuven (Other)
Overall Status
Recruiting
CT.gov ID
NCT06005415
Collaborator
(none)
52
1
2
3
17.4

Study Details

Study Description

Brief Summary

The aim of this study is to investigate whether using a coarse wheat fraction in wire-cut cookie making induces a lower glycemic response in healthy subjects compared to wheat flour.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Wire-cut cookie
N/A

Detailed Description

This study has a double-blind, randomized, cross-over design. During each of the two study visits, healthy participants will consume a standard portion of cookies. One cookie formulation will present a large amount of coarse wheat fraction, while the other formulation will include only wheat flour and will serve as a control. Blood glucose measurements will be taken postprandially at regular time points. Gastric emptying rate and oral processing behavior will be also object of study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Basic Science
Official Title:
Glycemic Response to an Innovative Cookie to Promote Human Health
Anticipated Study Start Date :
Aug 31, 2023
Anticipated Primary Completion Date :
Nov 30, 2023
Anticipated Study Completion Date :
Nov 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Test cookie

Wire-cut cookie portion (85 g) containing wheat flour, coarse wheat semolina, sucrose, vegetable shortening, water, sodium chloride, sodium bicarbonate and sodium octanoate.

Dietary Supplement: Wire-cut cookie
Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.

Active Comparator: Control cookie

Wire-cut cookie portion (85 g) containing wheat flour, wheat bran, sucrose, vegetable shortening, water, sodium chloride, sodium bicarbonate and sodium octanoate.

Dietary Supplement: Wire-cut cookie
Investigation of the impact of wheat particle size on the postprandial glycemic response, gastric emptying and oral processing behavior after consumption of wire-cut cookies.

Outcome Measures

Primary Outcome Measures

  1. Glucose response [10, 5 minute before and 10, 20, 30, 45, 60, 75, 90, 120, 150 and 180 minutes after consumption of test meal, both test day 1 and 2]

    Incremental area under the curve of blood glucose concentration (mM) after wheat-based wire-cut cookie consumption, measured through blood samples collected via finger-prick before eating (i.e. 10 and 5 minutes before ingestion) and at respective time points after consumption of test meal (i.e. 10, 20, 30, 45, 60, 75, 90, 120, 150 and 180 minutes).

Secondary Outcome Measures

  1. Peak rise of blood glucose [10, 5 minute before and 10, 20, 30, 45, 60, 75, 90, 120, 150 and 180 minutes after consumption of test meal, both test day 1 and 2]

    Difference between the highest postprandial blood glucose concentration and the baseline (expressed in mM), measured through blood samples collected via finger-prick before eating (i.e. 10 and 5 minutes before ingestion) and at respective time points after consumption of test meal (i.e. 10, 20, 30, 45, 60, 75, 90, 120, 150 and 180 minutes).

  2. Gastric emptying rate [0, 10, 20, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes after consumption of test meal, on test day 1]

    Measured through 13C-octanoic acid breath samples collected before eating (i.e. 0 minute) and at respective time points after consumption of test meal (i.e. 10, 20, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes).

  3. Gastric emptying rate [0, 10, 20, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes after consumption of test meal, on test day 2]

    Measured through 13C-octanoic acid breath samples collected before eating (i.e. 0 minute) and at respective time points after consumption of test meal (i.e. 10, 20, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180 minutes).

  4. Oral processing behavior (exposure time) [During test meal consumption, up to 10 minutes, on test day 1]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total oral exposure time (s).

  5. Oral processing behavior (exposure time) [During test meal consumption, up to 10 minutes, on test day 2]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total oral exposure time (s).

  6. Oral processing behavior (average bite size) [During test meal consumption, up to 10 minutes, on test day 1]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total average bite size (g per bite).

  7. Oral processing behavior (average bite size) [During test meal consumption, up to 10 minutes, on test day 2]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total average bite size (g per bite).

  8. Oral processing behavior (average chews per bite) [During test meal consumption, up to 10 minutes, on test day 1]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total average chews per bite.

  9. Oral processing behavior (average chews per bite) [During test meal consumption, up to 10 minutes, on test day 2]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total average chews per bite.

  10. Oral processing behavior (eating rate) [During test meal consumption, up to 10 minutes, on test day 1]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total eating rate (g per minute).

  11. Oral processing behavior (eating rate) [During test meal consumption, up to 10 minutes, on test day 2]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total eating rate (g per minute).

  12. Oral processing behavior (energy intake rate) [During test meal consumption, up to 10 minutes, on test day 1]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total energy intake rate (kcal per minute).

  13. Oral processing behavior (energy intake rate) [During test meal consumption, up to 10 minutes, on test day 2]

    Participants will be video-recorded to analyze oral processing behavior of the test meal. Number of bites, chews, swallows and time in mouth (s) will be annotated to derive total energy intake rate (kcal per minute).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Body mass index (BMI) range 18.5 - 25.0 kg/m2 at screening visit

  • Fasting whole blood glucose values < 6.3 mmol/L

  • Regular diet with 3 meals a day (at least 5 times a week)

  • Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigators on the basis of medical history

  • Willingness to maintain habitual diet, physical activity pattern, and body weight throughout the trial

  • Willingness to abstain from alcohol consumption and to avoid vigorous physical activity for 24 h prior to study visits

  • Adequate level of understanding spoken and written English

  • Willingness to report lifestyle factors such as level of physical activity and perceived psychological stress

  • Willingness to provide informed consent to participate in the study

Exclusion Criteria:
  • Failure to meet any one of the inclusion criteria

  • Recent participation in any clinical trial (< 90 days)

  • Pregnant or lactating or wishing to become pregnant in the period of the study

  • Known history of AIDS, hepatitis, diabetes mellitus (Type I and II), cardiovascular disease, any pathology (or recent surgical event) of the gastrointestinal system or any current metabolic or endocrine disease

  • Alcohol consumption of > 14 standard drinks for women and > 21 standard drinks for men per week

  • Currently smoking (have smoked in the last 28 days) or willingness to smoke during the study period

  • Celiac disease or gluten intolerance

  • Use of medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids the last 4 weeks before the screening visit

  • Use of antibiotics during the last three months

  • Reported slimming or medically prescribed diet

  • Unwillingness or inability to comply with the experimental procedures and to follow the safety guidelines

Contacts and Locations

Locations

Site City State Country Postal Code
1 KU Leuven/UZ Leuven Leuven Vlaams-Brabant Belgium 3000

Sponsors and Collaborators

  • KU Leuven

Investigators

  • Principal Investigator: Kristin Verbeke, Prof., KU Leuven

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kristin Verbeke, Professor, KU Leuven
ClinicalTrials.gov Identifier:
NCT06005415
Other Study ID Numbers:
  • S67376
First Posted:
Aug 22, 2023
Last Update Posted:
Aug 22, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kristin Verbeke, Professor, KU Leuven

Study Results

No Results Posted as of Aug 22, 2023